Targeted Vitamin D3 Supplementation Cuts Risk of Heart Attack Patients Having a Second ... - goo.gl/alerts/kqcdGS

Experts say this could be the worst flu season for a decade - here's why bbc.in/4oxEvFX

Men 4X more likely to commit suicide/Women 3X more likely to attempt Why disparity: 1)Men use guns 2)Women seek help 3)Risk factors work better in women Large & important study with 2 clear clinical implications: 1)Do especially careful suicide evals in men 2)Reduce gun access

Coronary artery calcium may be a predictor for all-cause mortality, including non-cardiac conditions medicalxpress.com/news/2025-… via @medical_xpress

PISCES: Among 1228 pts on HD, 4g omega-3 fatty acids vs corn oil placebo led to reduction in serious CV events (HR 0.57!). nejm.org/doi/full/10.1056/NE… @NEJM This is on the background of null STRENGTH (4g omega-3 carboxylic acids vs corn oil in high CV risk pts jamanetwork.com/journals/jam…) & numerous other null EPA/DHA vs placebo CV outcomes trials. Given the numerous EPA/DHA trials assessing CV outcomes, should we apply multiple hypothesis-correction when interpreting a positive trial? The effect estimate is large and hard to ignore. The side effect rate did not appear to be greater in the omega-3 fatty acid vs placebo comparison. So should we then recommend omega-3 fatty acids to pts on HD to reduce CV risk? The OTC fish oils are lower dose and of varying formulations. REDUCE-IT (nejm.org/doi/full/10.1056/NE…) has suggested that dose and formulation may be particularly relevant for omega-3 fatty acid supplements for CV outcomes. So this trial does not show that OTC fish oils are cheap and effective interventions for pts on HD. Pts at HD are at high CV risk despite standard interventions. So it’s plausible that observations of other interventions may not generalize. As with everything, further study is needed. #KidneyWeek #AHA25

Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis | New England Journal of Medicine nejm.org/doi/full/10.1056/NE… @NEJM #aha2025

#PISCES is likely one of the most impactful RCTs in the cardiovascular space in 2025. Oral supplementation with EPA and DHA significantly improved ALL cardiovascular outcomes in patients treated with maintenance hemodialysis, showing substantial benefits without safety concerns. This is a practice-changing study. Already well covered by @drjohnm in his podcast this week. @DLBHATTMD @djc795 @CMichaelGibson @drmikefarkouh @SABOURETCardio @venkmurthy @DFCapodanno @DavidLBrownMD @mmamas1973 @mirvatalasnag @DrMarthaGulati @pash22 @gcfmd @SripalBangalore @EricTopol @Hragy @gabrielsteg @kaulcsmc @ASNKidney @theheartorg @Medscape @ACCinTouch @ESCardioNews @AHAScience @NEJM nejm.org/doi/full/10.1056/NE…

VESALIUS a star of this lipid session at #AHA25. Substantial and deeply clinically meaningful benefit w Repatha in primary prevention. Baseline LDL-C 122. Notable ARRs, and 20% decrease in all-cause mortality! #AHA25

🚨 New breakthrough in prevention! 👉In the VESALIUS‑CV trial, Evolocumab added to high-intensity statin therapy reduced major adverse cardiovascular events (MACE) by 25% (HR 0.75; 95% CI 0.65-0.86) over ~4.6 years in patients who had no prior MI or stroke. 👉Absolute risk reductions: • ~1.8% for death from coronary disease, MI, or stroke. • ~2.8% when adding ischemia-driven revascularisation. 👉LDL-C fell ~55% to ~45 mg/dL—highlighting once again that “lower is better”, even before a first event. ☝️What this means for clinical practice: • This is the first PCSK9 inhibitor trial showing benefit in a “pre–first event” high-risk population, not just secondary prevention. • Identifying high-risk patients (e.g., established atherosclerosis, high-risk diabetes) before MI or stroke is crucial. • This supports aggressive LDL-C lowering to ~40 mg/dL in selected patients—even without prior event history. ☝️Take-home: For the right high-risk patient, adding evolocumab before the first major cardiovascular event can be a game-changer. Traditional prevention meets cutting-edge therapy. @society_eas nejm.org/doi/full/10.1056/NE…

Tomorrow the trial we are all waiting for at #AHA25 is VESALIUS-CV Trial #VESALIUSCV is the first trial to test a PCSK9 inhibitor for people who’ve never had a heart attack or stroke: moving lipid therapy deeper into primary prevention 📍top line results already released: in 12,000 high-risk adults without prior MI or stroke, adding Evolocumab (140 mg q2 wks) to optimized lipid-lowering therapy for ~4.5 yrs cut major CV events #HeartHealth #CVPrev #lipids #PCSK9i

What’s the best approach for #ASCVD patients with high Lp(a)? @CUAnschutz’s Prof G. Schwartz reviews how #Lpa modifies response to #PCSK9i, impacts lipid-lowering, outcomes, and #diabetes risk. Watch his video on @PCSK9Forum > pcsk9forum.org/what-have-pcs… #RCT

Lowering #LDLC with #PCSK9 inhibitors and/or #statins greatly improves plaque regression and stability. @ProfSNicholls reviews key evidence, imaging advances, and why plaque stabilisation reduces #CVD events in a new @PCSK9Forum presentation > pcsk9forum.org/pcsk9-targete… #cardiology

🎉 Welcome back to #TrigTriviaTuesday! Haven’t seen this yet? 👀 Now’s the time to #BoostUrTrigIQ! 📽️ Watch this educational module from expert @EliotBrinton as he explains how triglycerides impact pancreatitis and ASCVD: 👉 piped.video/lMZJ2bac3RE 🧠 By the end of this module, you’ll understand the key pathways of triglyceride metabolism, identify what drives dysregulation, and build a strong foundation for evaluating and managing patients with elevated triglycerides. #HTG #metabolichealth #cardiotwitter @EliotBrinton @lipiddoc @SethJBaumMD @ArchnaBajajMD @drmaggarwal @nationallipid @ASPCardio @NatPancFdn @livingwithfcs @TheAACE @HeartNurses @ionispharma @ArrowheadPharma @Amarincorp

My view: Genetic studies that find 200+ genes related to any given mental disorder are complete flops re diagnosis/treatment planning/explaining causation. They prove just 1 thing- mental disorder causation is ridiculously complicated/rarely explainable. share.google/OmqAjEBTOV0cCpJ…

4 years of vitamin D supplementation (2000 IU/day) significantly slowed telomere shortening compared to placebo. Telomeres shorten with age and are linked to disease risk, suggesting vitamin D may help counteract biological aging.

The transition from weekend relaxation to work mode can be a tough 180-degree turn. In that way, Sunday scaries are a normal reaction to adjusting to a different role and change. Help calm the angst that can come with the start of a new work week by adopting a positive mindset, planning an activity and getting some exercise.

New causal genetic evidence shows it's likely that statins (HMGCR), PCSK9 inhibitors, ezetimibe (NPC1L1), and other cholesterol lowering drugs not only reduce heart disease risk, but also prevent dementia!

A 14 years old girl shot her mother to death, and laughed in court as if nothing happened 😱😢

Stopping Omega-3s? Benefits May Disappear “Rapidly,” Study Warns scitechdaily.com/stopping-om…

Where do experts disagree in cardiovascular prevention? Find out at the Controversies in Prevention session featuring @RonBlankstein @lesleejshaw @BudoffMd @DrMarthaGulati & Ann Marie Navar at the #SCCTPrevention on November 1. Register: bit.ly/3J5OkeE